Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in patients at risk of rapidly progressive autosomal dominant polycystic kidney disease
jRCT2080224131Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Venglustat with Placebo (2 arms). Primary endpoint: Annualized rate of change in total kidney volume (TKV). Started Nov 2018; status: completed.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCT2080224131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224131.